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parC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi
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We have isolated in vitro fluoroquinolone-resistant mutants of the Lyme disease agent, Borrelia burgdorferi.
Mutations in parC, which encodes a subunit of topoisomerase IV, were associated with loss of susceptibility to
sparfloxacin, moxifloxacin, and Bay-Y3118, but not ciprofloxacin. This is the first description of fluoroquin-
olone resistance in the spirochete phylum.
Borrelia burgdorferi, a bacterium in the spirochete phylum, is
the causative agent of Lyme disease (27, 33, 34). It has an
unusual genome comprised of a small linear chromosome and
a large complement of both linear and circular plasmids (1,
11). Both DNA gyrase and topoisomerase IV map to the linear
chromosome in B. burgdorferi (11, 15, 19, 31).
DNA gyrase and topoisomerase IV are prokaryotic type II
topoisomerases, a group of enzymes that alter DNA topology
by breaking and resealing both strands of the double helix.
DNA gyrase maintains negative supercoiling in the cell, and
topoisomerase IV relaxes supercoiled DNA and decatenates
daughter DNA after replication (8, 9, 26, 41). Both DNA
gyrase and topoisomerase IV are tetramers comprised of two
A subunits (GyrA or ParC) and two B subunits (GyrB or
ParE). The A subunits are involved in the double-stranded
nicking and resealing reactions, while the B subunits are re-
sponsible for providing energy through ATP hydrolysis (26).
Fluoroquinolones are chemotherapeutic agents that target
type II topoisomerases by preventing the resealing step in the
topoisomerase mechanism (7, 8, 13, 22, 35). Fluoroquinolone
treatment results in ternary DNA-topoisomerase-fluoroquino-
lone complexes that cause lethal double-stranded DNA breaks
(3, 17, 40) and block transcription and replication (36, 37).
Resistance to fluoroquinolones usually maps to fluoroquino-
lone resistance-determining regions (QRDRs) that are found
in the A subunits of DNA gyrase and topoisomerase IV, en-
coded by gyrA and parC, respectively (4, 25, 39). Mapping a
first-step mutation to one of these genes indicates that the
respective gene encodes the primary target of fluoroquinolo-
nes (7, 8, 14, 23). Gram-positive bacteria tend to have topo-
isomerase IV as the primary target, while gram-negative bac-
teria tend to have a primary target of DNA gyrase; however,
the primary target also depends on the particular fluoroquin-
olone (3, 10, 18, 24, 39).
We have isolated fluoroquinolone-resistant first-step mu-
tants of B. burgdorferi by selection in increasing doses of three
different fluoroquinolones in vitro. Although B. burgdorferi is
not susceptible to many fluoroquinolones (5, 12, 20, 21, 30),
recently developed fluoroquinolones demonstrate some ther-
apeutic potential (16). This study provides the first description
of fluoroquinolone resistance in the spirochete phylum and is
only the second report, to our knowledge, in which genomic
mutations have been associated with antibiotic resistance in B.
burgdorferi (32).
Selection of fluoroquinolone-resistant mutants. High-pas-
sage B. burgdorferi strain B31 was grown at 34°C in Barbour-
Stoenner-Kelly (BSK)-H medium (Sigma). The fluoroquinolo-
nes moxifloxacin, ciprofloxacin, sparfloxacin, and Bay-Y3118
were generously provided by Peter Heisig (Abteilung
Pharmazeutische Biologie und Mikrobiologie, Institut für
Pharmazie, Universität Hamburg). The concentration at which
50% of growth is inhibited (IC50) of each fluoroquinolone was
determined for wild-type strain B31 (Table 1) using suscepti-
bility assays as previously described (30). Fluoroquinolones at
the IC50 were added to B31 cultures. Each culture was evalu-
ated by dark-field microscopy for growth after 7 days. Non-
growing cultures were continually passaged 1:10 into the iden-
tical antibiotic concentration until growth was observed by
dark-field microscopy, and growing cultures were diluted 10-
fold into medium containing twice the concentration of the
respective fluoroquinolone. Cultures growing in 16-fold the
wild-type IC50 of a particular fluoroquinolone were plated for
isolation in semisolid medium containing 10-fold the IC50, and
cultures growing in 128-fold the wild-type IC50 were plated on
100-fold the IC50, as previously described (29). Five to 10
colonies were selected from each plate; no mutant was identi-
fied from ciprofloxacin-treated cultures despite exhaustive ef-
forts.
Mutations in parC of fluoroquinolone-resistant B. burgdor-
feri. DNA was isolated from fluoroquinolone-resistant B. burg-
dorferi as previously described (31). The region of the gyrA
gene (BB0435) encoding the QRDR was amplified by PCR
with primers gyrB 1885F (5-GTAATTAATCTTGATGTGT
AA-3) and gyrA 538R (5-TTCCAACAGCAATTCCAC-3).
The region of the parC gene (BB0035) encoding the QRDR of
topoisomerase IV was amplified with parC 68F (5-CTATTG
CTAGTGTTGTTGATGGG-3) and parC 311R (5-CTAGA
AGCAGAAGCAGGATCAC-3).
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The sequences of the 570-bp gyrA region in all fluoroquin-
olone-resistant mutants were identical to that of the wild-type
strain B31, but all nine strains sequenced had mutations in the
244-bp parC region (Table 2). Mutants selected in Bay-Y3118,
an experimental fluoroquinolone not used clinically, contained
one of two mutations, T69K or S70P. Mutant KG1R2, which is
ninefold more resistant to Bay-Y3118 than parental B31, had a
C-to-A transversion at nucleotide 206 in parC that resulted in
a Thr-69-to-Lys change. Mutant KG1R1, which is eightfold
more resistant than the wild type to Bay-Y3118, had a T-to-C
transition at nucleotide 208 in parC that encoded a Ser-70-to-
Pro change. Mutant KG1S3, selected in sparfloxacin, had a
C-to-G transversion at nucleotide 206 in parC that resulted in
a Thr-69-to-Arg change.
Mutants KG1S1 and KG1M1, which resulted from indepen-
dent selection in sparfloxacin and moxifloxacin, respectively,
had an A-to-G transition at nucleotide 218 of parC that en-
coded a Glu-73-to-Gly change. This E73G mutation was asso-
ciated with 14-fold resistance to moxifloxacin and 11-fold re-
sistance to sparfloxacin. Selection in a higher level of
sparfloxacin resulted in isolation of mutant KG2S5 with a
change of the same glutamic acid residue to a lysine (E73K).
This was the result of a G-to-A transition at nucleotide 217.
Growth was assayed by dark-field microscopy with a Petroff-
Hausser counting chamber as previously described (2). The
growth rates of the parC mutants were found to be slower than
that of the wild type (Fig. 1), and KG2S5 (E73K) has an
extended lag phase (Fig. 1D and data not shown). Preliminary
observations that KG1R2 (T69K) requires frequent passage to
maintain viability (data not shown) suggest a decreased sur-
vival in stationary phase, which may be related to this mutant
reaching a greater cell density than even the wild-type clone
(Fig. 1A). In addition, examination by dark-field microscopy
reveals that KG1R2 is smaller than B31 and the other mutants;
the morphology of the other mutants is indistinguishable from
that of B31 (data not shown).
Conclusions. Fluoroquinolones are potent chemotherapeu-
tic agents that target the A subunit of both DNA gyrase and
topoisomerase IV. We have isolated fluoroquinolone-resistant
mutants of B. burgdorferi and have mapped single point muta-
tions to the QRDR of the parC gene encoding the A subunit of
topoisomerase IV. This indicates that the primary target of the
fluoroquinolones moxifloxacin, sparfloxacin, and Bay-Y3118 in
B. burgdorferi is topoisomerase IV. This is the first example of
mutations that confer resistance to fluoroquinolones in the
Lyme disease agent or any spirochete.
A previous study by Kraiczy et al. (20) determined the flu-
oroquinolone susceptibility of B. burgdorferi. Although the col-
lection of fluoroquinolones studied was broader and the
method of assaying susceptibility differed from our study, the
data are consistent. Their MICs for strain B31 are about twice
our IC50 values. We and others have also previously reported
similar susceptibilities to ciprofloxacin, moxifloxacin, or spar-
floxacin (5, 12, 21, 30). Susceptibility of B. burgdorferi to newer
fluoroquinolones (20) suggests that these antibiotics have po-
tential as therapeutic agents for Lyme disease (16).
B. burgdorferi is, to an extent, naturally resistant to fluoro-
quinolones, and we hypothesize that this is due to the presence
of a glutamine at position 86 in GyrA, a highly conserved
position occupied by a serine residue in almost all bacterial
species, with the exception of mycobacteria, Helicobacter pylori,
and spirochetes (Fig. 2) (7). The homolog of this serine is
mutated in fluoroquinolone-resistant strains of several differ-
ent species (7, 8, 14, 23, 28). In Escherichia coli, a single
mutation of Ser-83 (homologous to Gln-86 of B. burgdorferi) to
Trp in GyrA prevents binding of the fluoroquinolone norfloxa-
cin (38) and results in 32-fold resistance to ciprofloxacin (39);
other substitutions also confer resistance. We have been un-
able to isolate ciprofloxacin-resistant mutants, and the mutants
that are resistant to the other fluoroquinolones are not resis-
tant to ciprofloxacin (Table 1). The reason for the intractability
is not clear, although it is likely due to subtle structural differ-
ences among the antibiotics. Furthermore, this result suggests
that the choice of antibiotic therapy should consider both the
level of susceptibility and the frequency of resistance (6). In-
terestingly, the mutants are not necessarily most resistant to
the fluoroquinolone used to select them: KG1R2 and KG1R1
were isolated in Bay-Y3118 but are most resistant to sparfloxa-
cin and moxifloxacin, respectively (Tables 1 and 2). We hy-
pothesize that all four classes of mutant can be selected by
each of the three fluoroquinolones; our failure to identify each
class of mutation under selective pressure from each of the
antibiotics is likely a result of limited sample size. However,
different mutants have different resistance profiles. KG1R2
TABLE 1. Fluoroquinolone susceptibility of B. burgdorferi wild-type strain B31 and mutants
Fluoroquinolone
IC50 in g ml1 (fold resistance)a
B31 (wild type) KG1R2 (T69K) KG1R1 (S70P) KG1M1 (E73G) KG2S5 (E73K)
Bay-Y3118 0.18 1.7 (9) 1.4 (8) 0.8 (4) 4.2 (23)
Sparfloxacin 0.23 9.2 (42) 10 (43) 2.4 (11) 15 (75)
Moxifloxacin 0.38 9.8 (26) 17 (45) 5.2 (14) 5.8 (15)
Ciprofloxacin 0.49 0.6 (1.2) 0.9 (1.8) 0.6 (1.2) 1.2 (2.5)
a Values in parentheses represent fold resistance compared to wild-type B31.
TABLE 2. Fluoroquinolone selection of ParC mutants
in B. burgdorferi
Straina Fluoroquinoloneselection (g ml1) ParC mutation
KG1R2 Bay-Y3118 (2) Thr-69 to Lys (T69K)
KG1R1, KG1R3 Bay-Y3118 (2) Ser-70 to Pro (S70P)
KG1M1, KG1M3 Moxifloxacin (4) Glu-73 to Gly (E73G)
KG1S1 Sparfloxacin (2) Glu-73 to Gly (E73G)
KG1S3 Sparfloxacin (2) Thr-69 to Arg (T69R)
KG2S5, KG2S2 Sparfloxacin (20) Glu-73 to Lys (E73K)
a Strains in bold were further characterized in this study.
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and KG2S5 are most resistant to sparfloxacin, while KG1R1
and KG1M1 are most resistant to moxifloxacin. Again, this
likely reflects slightly different interactions between each fluo-
roquinolone and topoisomerase IV. Two mutations are substi-
tutions at Glu-73, which is homologous to a conserved acidic
residue (Asp-87 in E. coli GyrA) that is commonly mutated in
fluoroquinolone-resistant strains (7, 8, 28). KG2S5, with an
E73K mutation, is more resistant to the fluoroquinolones, es-
pecially Bay-Y3118 and sparfloxacin, than KG1M1, with an
E73G mutation. E73G replaces the acidic residue with a neu-
tral amino acid, and E73K replaces it with a basic amino acid.
This suggests that these fluoroquinolones contact topoisomer-
ase IV through an ionic interaction that is lost in E73G and
replaced with repulsion in E73K. We are currently using flu-
oroquinolone-resistant parC as a counterselectable marker for
genetic studies in B. burgdorferi (S. F. Bundle and D. S. Sam-
uels, unpublished data).
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FIG. 1. Growth of the B. burgdorferi wild-type strain and fluoroquinolone-resistant parC mutants. Growth was assayed by inoculating cultures
of B. burgdorferi strains B31 (closed circles), KG1R2 (A; squares), KG1R1 (B; inverted triangles), KG1M1 (C; triangles), and KG2S5 (D;
diamonds) at 104 cells ml–1 in 10 ml of BSK-H medium on day 0. Cultures were appropriately diluted (ranging from 1:5 to 1:40) in phosphate-
buffered saline, and live cells were enumerated in a Petroff-Hausser counting chamber. Plotted are the means of four independent experiments
for days 3 to 5, three independent experiments for days 6 to 9, and two independent experiments for day 10; error bars represent standard errors.
FIG. 2. Alignment of a portion of the QRDRs of B. burgdorferi
(Bb), Streptococcus pneumoniae (Sp), and E. coli (Ec) ParC and GyrA
proteins. Amino acid residues 62 to 80 of B. burgdorferi ParC, 78 to 96
of B. burgdorferi GyrA, 72 to 90 of Streptococcus pneumoniae ParC, 74
to 92 of Streptococcus pneumoniae GyrA, 51 to 69 of E. coli ParC, and
76 to 94 of E. coli GyrA were aligned using ClustalW (embedded in
MacVector 7.2); the numbers at the top refer to the ParC protein of B.
burgdorferi and indicate residues that are mutated in the fluoroquin-
olone-resistant strains (T69, S70, and E73). The asterisk indicates the
highly conserved serine that confers fluoroquinolone resistance when
mutated (homologous to S83 in the GyrA protein of E. coli);  indi-
cates a conserved acidic residue that is also often mutated.
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